PCSK9 and myocardial infarction: Langsted et al. [110] showed that PCSK9 R46 L carriers have lower levels of Lp(a) and LDL cholesterol and also a reduced risk of myocardial infarction and of aortic stenosis, suggesting that PCSK9 inhibitors may have a role in patients with aortic stenosis.